Young J, et al. - The intention of the experts was to document changes in liver function in patients with Cushing's syndrome (CS) treated with ketoconazole (KTZ). A necessity arose for close monitoring of liver enzymes particularly during the first 6 months of treatment. Findings revealed the occurrence of liver enzyme abnormalities within four weeks, which were asymptomatic and could be reversed on timely discontinuation of KTZ.